Sales 2024 * | - | Sales 2025 * | - | Capitalization | 22.4M 16.37M 1.29B |
---|---|---|---|---|---|
Net income 2024 * | -61M -44.56M -3.52B | Net income 2025 * | -68M -49.68M -3.92B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.33
x | P/E ratio 2025 * |
-0.35
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.88% |
Latest transcript on Aptose Biosciences
Managers | Title | Age | Since |
---|---|---|---|
William Rice
CEO | Chief Executive Officer | 65 | 27/10/13 |
C. Payne
DFI | Director of Finance/CFO | 61 | 26/06/22 |
Chief Tech/Sci/R&D Officer | - | 31/10/19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Denis Burger
BRD | Director/Board Member | 80 | 18/09/07 |
Bernd Seizinger
BRD | Director/Board Member | 67 | 12/09/22 |
Mark Vincent
BRD | Director/Board Member | 71 | 18/09/07 |
1st Jan change | Capi. | |
---|---|---|
+19.41% | 45.51B | |
-8.62% | 38.52B | |
+38.90% | 38.13B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |